CUAMC
ORIC icon

China Universal Asset Management Company’s Oric Pharmaceuticals ORIC Stock Holding History

China Universal Asset Management Company’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
22,153
+4,344
+24% +$39.4K 0.01% 341
2026
Q1 		$226K Buy
17,809
+1,939
+12% +$22K 0.02% 341
2025
Q4 		$130K Sell
15,870
-11,154
-41% -$128K 0.01% 388
2025
Q3 		$324K Buy
27,024
+12,746
+89% +$134K 0.03% 284
2025
Q2 		$145K Buy
14,278
+31
+0.2% +$208 0.01% 337
2025
Q1 		$79.5K Sell
14,247
-716
-5% -$6.26K 0.01% 376
2024
Q4 		$121K Buy
14,963
+1,395
+10% +$12.8K 0.01% 374
2024
Q3 		$139K Buy
13,568
+5,646
+71% +$55.8K 0.02% 328
2024
Q2 		$56K Sell
7,922
-5,000
-39% -$44.8K 0.01% 348
2024
Q1 		$178K Buy
12,922
+6,617
+105% +$78.6K 0.02% 305
2023
Q4 		$58K Buy
+6,305
New +$45.6K 0.01% 354
2022
Q4 		– Sell
-370
Closed -$1K – 438
2022
Q3 		$1K Buy
+370
New +$1.48K ﹤0.01% 405

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

China Universal Asset Management Company's ORIC Position: Q2 2026 in Review

China Universal Asset Management Company increased its Oric Pharmaceuticals (ORIC) stake by 24% in Q2 2026, buying an estimated $39.4K and bringing the position to 22,153 shares worth $240K. The position accounts for 0.01% of the portfolio, ranked #341.

China Universal Asset Management Company first reported a position in ORIC in Q3 2022 and has held it in 12 quarters since. The position peaked at $324K in Q3 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • China Universal Asset Management Company held 22,153 shares of Oric Pharmaceuticals worth $240K as of Q2 2026.
  • China Universal Asset Management Company bought 4,344 Oric Pharmaceuticals shares in Q2 2026, an estimated $39.4K.
  • Oric Pharmaceuticals made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #341 holding.
  • China Universal Asset Management Company first reported a position in Oric Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
  • China Universal Asset Management Company's Oric Pharmaceuticals position peaked at $324K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.